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BACKGROUND. Previous epidemiologic investigations of the associations of sex-steroid
hormones and benign prostatic hyperplasia (BPH) have focused on predominately white
populations. The objective of this study was to evaluate potential associations of body mass
index (BMI), cigarette smoking, use of alcohol, and endogenous sex-steroid hormones with
prostate volume in a population-based sample of African American (AA) men, ages 40–79 yr.
METHODS. A total of 369 AA men without clinical evidence of prostate cancer were identified
in the Flint Men’s Health Study by using a population-based sampling procedure. All subjects
underwent a complete urologic evaluation that included prostate volume determination by
transrectal ultrasonography and serum assays for androgens and estrogens.
RESULTS. After age adjustment, BMI (weight (kg)/height (m)2) was positively correlated with
increasing levels of androstanediol glucuronide (AG), estradiol (E2), estrone sulfate (E1S), and
the ratios of E2:total testosterone (TT) and E2:free testosterone (FT); however, increasing BMI
was negatively correlated with androstenedione (AD), FT, TT, and sex hormone-binding
globulin (SHBG). Multivariable regression models demonstrated that prostate volume in-
creased with age (P< 0.001) and BMI (P¼ 0.02) and decreased with increasing levels of SHBG
(P¼ 0.01). Larger prostatic volumes were also marginally associated with increasing levels of
TT (P¼ 0.058).
CONCLUSION. Circulating serum levels of SHBG and endogenous sex-steroid hormones are
correlated with prostate volume and potentially impact the natural history of BPH. However,
longitudinal studies are needed to demonstrate the temporal relationships of hormones and
growth factors in the pathogenesis of BPH in AA men. Prostate 53: 322–329, 2002.
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INTRODUCTION
Benign prostatic hyperplasia (BPH) is the most
common neoplasm in elderly men, afflicting more than
50% of men by age 60 years and 90% by age 85 years [1].
BPH leads to a progressive enlargement of the prostate
gland, causing both obstructive and irritative lower
urinary tract symptoms (LUTS). The lifetime risk for a
50-year-old man to undergo a prostatectomy for BPH
has been estimated to be as high as 40% [2] and, in the
United States, BPH results annually in more than
380,000 hospitalizations [3]. BPH generates considerable
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morbidity and health care costs, and with the aging
of the general population, its prevalence is likely to
increase.
The causes of BPH have not been fully elucidated,
although androgen induction of BPH has been well
established [4–6]. The prostate is heavily dependent on
androgens for growth and maintenance of its structural
and functional integrity. Estrogens, and in particular
the elevated plasma free estradiol/free testosterone
ratio after age 50, play a putative role in the pathogen-
esis of BPH. The increase in serum and intraprostatic
estrogen/androgen concentration ratios, as a result
of declining testicular function and increasing rate of
peripheral aromatization, are associated with stromal
hyperplasia [7–10].
Population-based studies that have evaluated the
interrelationships of sex-steroid hormones in associa-
tion with BPH have focused on predominately white
populations. The Flint Men’s Health Study (FMHS) is
investigating the natural history of BPH and prostate
cancer among African American (AA) men. A prior
report from the FMHS has shown a positive association
between insulin-like growth factor binding protein-3
(IGFBP-3) and prostate volume [11]. Because nonhor-
monal risk factors such as cigarette smoking, chronic
use of alcohol, and BMI may alter serum sex-steroid
hormone levels [9,12], this study assesses the nature
of the interrelationships of these epidemiologic risk
factors and endogenous sex-steroid hormones with
prostate volume in a population-based sample of
AA men.
MATERIALSANDMETHODS
This analysis is based on data from the FMHS, a
study of prostate cancer and BPH among AA men
residing in Flint, Michigan. The Institutional Review
Board at the University of Michigan Medical School
reviewed and approved the study protocol. Details of
the study have been described elsewhere [13–15].
Briefly, probability sampling of households or group
dwelling units was undertaken in Flint, Michigan, and
in select census tracts in Beecher Township. Subjects
were stratified by age, representing four 10-year age
groups (40–49, 50–59, 60–69, and 70–79 years). Be-
cause of the established relationship between age and
prostatic morbidity, the pool of eligible subjects aged
60–79 years was oversampled.
Trained interviewers contacted each sampled house-
hold in person and conducted a short screening inter-
view to identify and select eligible respondents for
the epidemiologic survey. A total of 943 age-eligible
AA men were identified for participation in the FMHS
in-home interview. The interview included questions
on health status, sociodemographic characteristics,
tobacco and alcohol consumption, past medical his-
tory, and history of LUTS.
After completion of the interview, eligible men were
invited to participate in a comprehensive urologic exa-
mination. Men were ineligible for the examination
if they reported having prostate cancer or having had a
prostatectomy. The clinical exam, in general scheduled
within 8 weeks of the in-home interview, included a
standardized questionnaire of LUTS, height and weight
measurements, digital rectal examination (DRE), and
determination of urinary flow rate. Participants with an
abnormal DRE or elevated total serum prostate speci-
fic antigen (PSA) concentration, namely greater than
4.0 ng/ml, were referred for prostate biopsy. Transrec-
tal ultrasonography (B&K Medical, Denmark; Hitachi
Medical Systems, Tarrytown, NY) was also perform-
ed on all subjects, and two urologists independently
measured the length, width, and height of the prostate.
Prostate volume was calculated by using the formula
for a prolate ellipsoid [(p/6) (width (maximal trans-
verse dimension)) (length (maximal anteroposte-
rior dimension)) (height (maximal superior-inferior
dimension))]. A third reader re-measured the prostate
dimensions when differences were recorded of more
than 50% in any dimension between the first two
readers. The prostate volume used in this analysis
represents the mean calculated volume of the two
readers, or if a third reading was performed, the mean
of the two closest total volume estimates.
HormoneAnalysis
To minimize the confounding effects of diurnal
variations in concentration levels of hormones and
growth factors, blood draws were scheduled between
9:00 and 11:00 AM. Sixty-two (16.8%) of 369 blood draws
occurred outside this time window, with 29 occurring
before 9:00 AM and 33 after 11:00 AM. The mean con-
centration levels of dehydroepiandrosterone sulfate
(DHEAS), estrone sulfate (E1S), and the ratio of estra-
diol (E2) to total testosterone (TT), were higher in the
men who had blood drawn after 11:00 AM. Exclusion of
the 33 men with late blood draws did not alter study
results (data not presented); thus, they are included in
the analyses presented here. Subjects were asked to
refrain from sexual activity for 48 hr and to fast the
morning of their scheduled appointment. A total of
50 cc of blood was obtained, from which approximately
36 cc of sera was separated and stored in polystyrene
tubes. The tubes were surrounded by a frozen re-
frigerant pack that was sealed inside a refrigerated
cooler and transported by means of overnight delivery
to the University of Michigan, Ann Arbor, within 48 hr
of the initial blood draw. Serum was immediately
labeled and stored in a 808C freezer. Analyses for
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androstenedione (AD) and free testosterone (FT) were
performed at the Chemical Pathology Laboratory at
the University of Michigan Hospital. Analyses for
DHEAS, TT, E2, E1S, prolactin (PRLN), and sex-
hormone binding globulin (SHBG) were performed at
the Reproductive Sciences Laboratory. The following
hormones were measured by commercially available
enzyme-linked immunosorbent assays (Diagnostic
Systems Laboratory, Inc., Webster, TX), with their
respective inter- and intra-assay coefficients of varia-
tion, and the number of men for whom results were
obtained given in parentheses: androstanediol glucur-
onide (AG) (5%, 11%; n¼ 353), insulin-like growth
factor-1 (IGF-1) (4%, 6%; n¼ 353), and IGFBP-3 (6%, 9%;
n¼ 352). AD (11.6%, 6%; n¼ 354), DHEAS (18.14%,
12.53%; n¼ 366), FT (6.5%, 7.3%; n¼ 354), TT (8.68%,
6.82%; n¼ 365), E2 (10.21%, 6.375%; n¼ 355), E1S
(10.27–10.93%, 4.11–8.02%; n¼ 358), PRLN (5.83%,
3.03%; n¼ 366), and SHBG (18.95%, 10.31%; n¼ 366)
were quantified by commercially available chemilumi-
nescent immunoassays provided by Bayer Diagnostics
(Pittsburgh, PA).
Lifestyle andAnthropometric Risk Factors
Subjects’ smoking history was classified as former
smokers (at least 100 cigarettes smoked in a lifetime),
current smokers, and never smokers. Current smokers
reported the number of cigarettes smoked per day over
the past 12 months. The usual number of drinks per
week for beer, wine, and hard liquor consumption was
assessed for both usual weekday and weekend con-
sumption, with volume sizes specified on the ques-
tionnaire. For those men who reported ever consuming
alcohol, data were recorded for age when they began
to drink each type of beverage, whether they were
currently drinking and, if they have stopped, the age at
which they discontinued. Subjects were classified as
never, former, or current alcohol drinkers, with current
drinkers defined as those who reported having at
least one drink of beer, wine, or liquor per month for at
least the past 6 months. To estimate total alcohol intake
in grams (g)/day, servings of specified types of
alcoholic beverages were multiplied by g/serving
(liquor¼ 15.1, beer¼ 13.2, and wine¼ 10.8 g/serving)
[12]. Body mass index [BMI¼weight (kg)/height (m)2]
was calculated based on height and weight measure-
ments recorded at the clinical examination and
categorized into tertiles of BMI.
Statistical Analyses
Distributions of demographic, lifestyle, and anthro-
pometric variables were examined by 10-year age
groups, and Mantel Haenszel chi-square tests were
performed to assess trends across ordered categories.
Spearman correlation coefficients (r) were calculated
to evaluate the relationships between age and serum
hormone levels. The ratios of E2 to TT and E2 to FT were
computed for each 10-year age group. Partial correla-
tion coefficients were calculated to assess the relation-
ship between (1) prostate volume and serum hormones,
and (2) BMI and serum hormones while controlling
for the possible confounding effects of age. Analysis
of variance was performed to assess relationships be-
tween lifestyle and anthropometric variables with pro-
state volume. Multivariable linear regression models
were then constructed to assess the association between
prostate volume and each hormone, while adjusting
for age, BMI, and tobacco and alcohol consumption.
As prior analyses of this data set found an association
between IGFBP-3 and prostate volume, we also adjust-
ed for this hormone [11]. Forward and backward
model-building procedures were used in regression
analyses to produce the most parsimonious subset of
explanatory factors associated with prostate volume.
To adjust for over sampling of the older age groups,
age-specific sampling weights were used to calcu-
late overall sample means and to fit multivariable
linear regression models. The SURVEYMEANS and
SURVEYREG procedures in SAS version 8.2 (SAS
Institute, Inc., Cary, NC) were used to obtain the
correct variance estimations for overall sample means
and estimated beta coefficients. Statistical significance
was set at an alpha level of 0.05.
RESULTS
A total of 943 age-eligible AA men were identified
for participation in the FMHS in-home interview, 819
(87%) of whom consented to be interviewed. Of the
men interviewed, 87 were ineligible to participate in the
clinical phase due to a prior diagnosis of prostate cancer
(n¼ 55) or prior surgery (n¼ 32), and 2 were later found
to be age-ineligible. Of the remaining 730 men, 11 were
excluded from further analyses due to a positive biopsy
for cancer, and 350 did not complete the clinical evalua-
tion. Clinical participation rates differed by age cate-
gory, with older men less likely to participate than
younger men; however, nonparticipants did not differ
significantly from participants in other demographic or
lifestyle characteristics (data not presented). The final
study population consisted of 369 men, representing
50.5% of those eligible to participate in the clinical
exam. The designation of clinical and demographic
characteristics of the study population has been
presented in previous publications [13–15].
Overall, 60.1% of the men were either married or
living with a partner, 74.2% reported that they had
completed a high school education or equivalent, and
nearly 65% reported an annual income of less than
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$50,000 (Table I). With respect to smoking status and
use of alcohol, 44.5% of the men were current smokers
and 53.2% currently consumed alcohol, but the pre-
valence of smoking and drinking decreased with age.
Among current smokers, 47.4% reported having
smoked 20 cigarettes or more per day over the past
year. The median BMI was 27.7 kg/m2 (interquartile
range, 23.8–31.3 kg/m2), and approximately one third
of the study population was classified as being obese
(BMI 30 kg/m2) [16]. The distribution of BMI did not
vary by age.
The median and interquartile ranges for the panel
of hormones investigated were as follows: AG (6.4, 4.6–
8.8 ng/ml), AD (1.1, 0.8–1.3 ng/ml), DHEAS (140.9,
84.5–202.7 mg/dl), FT (13.1, 9.5–17.4 pg/ml), TT
(582.4, 423.9–757.1 ng/ml), E2 (29.5, 23.4–36.9 pg/ml),
E1S (1.9, 1.3–3.0 pg/ml), PRLN (7.1, 5.4–10.1 ng/ml),
and SHBG (29.6, 21.3–43.1 nmol/l).
There were substantial correlations between TT and
SHBG (r¼ 0.60) and TT and FT (r¼ 0.58), and weaker
correlations between TT and AD (r¼ 0.38) and TT and
E2 (r¼ 0.27) (Table II). E1S was negatively correlated
with TT (r¼0.19) and SHBG (r¼0.34). Both E2
and E1S were positively correlated with AD, DHEAS,
and FT. SHBG was negatively correlated with DHEAS
(r¼0.15) and E1S (r¼0.34). Serum levels of AG
were not correlated with the levels of other hormones.
Overall, the median prostate volume was 24.9 g
(interquartile range¼ 19.4–31.6 g). There was a sig-
nificant correlation between age and prostate volume















Married/living with partner 218 (60.1) 70 (64.8) 62 (53.5) 56 (60.9) 30 (57.7)
Divorced/separated/widowed 121 (30.7) 24 (22.2) 48 (41.4) 28 (30.4) 21 (40.4)
Never married 29 (9.1) 14 (13.0) 6 (5.2) 8 (8.7) 1 (1.9)
Completed high school 256 (74.2) 90 (83.3) 88 (75.9) 54 (58.1) 24 (46.2) 0.0001a
Income 0.0001a
<$15,000 104 (26.7) 24 (23.1) 31 (27.9) 26 (28.3) 23 (45.1)
$15,000–$29,999 83 (20.1) 12 (11.5) 26 (23.4) 28 (30.4) 17 (33.3)
$30,000–$49,999 62 (17.4) 19 (18.3) 13 (11.7) 23 (25.0) 7 (13.7)
$50,000 109 (35.8) 49 (47.1) 41 (36.9) 15 (16.3) 4 (7.8)
Smoking status 0.0001
Current smoker 150 (44.5) 58 (53.7) 53 (45.7) 24 (25.8) 15 (28.9)
Former smoker 139 (33.4) 27 (25.0) 36 (31.0) 47 (50.5) 29 (55.8)
Never smoker 80 (22.1) 23 (21.3) 27 (23.3) 22 (23.7) 8 (15.4)
Cigarettes smoked per dayb 0.025a
1–9 34 (20.0) 10 (17.2) 12 (22.6) 4 (16.7) 8 (53.3)
10–19 49 (32.5) 17 (29.3) 21 (39.6) 7 (29.2) 4 (26.7)
20 67 (47.4) 31 (53.5) 20 (37.7) 13 (54.2) 3 (20.0)
Alcohol drinking status 0.049
Current drinker 183 (53.2) 68 (63.0) 56 (48.3) 40 (43.0) 19 (37.3)
Former drinker 129 (32.4) 27 (25.0) 42 (36.2) 37 (39.8) 23 (45.1)
Never drinker 56 (14.4) 13 (12.0) 18 (15.5) 16 (17.2) 9 (17.7)
Alcohol intake (g/day)c 0.016a
25.27 63 (31.9) 14 (20.6) 24 (42.9) 20 (50.0) 5 (26.3)
25.28–65.31 60 (32.5) 23 (33.8) 17 (30.4) 12 (30.0) 8 (42.1)
65.32 60 (35.6) 31 (45.6) 15 (26.8) 8 (20.0) 6 (31.6)
Body mass index (kg/m2) 0.108a
<25 119 (31.4) 30 (27.8) 41 (35.3) 30 (32.3) 18 (34.6)
25–29.9 134 (35.2) 36 (33.3) 41 (35.3) 35 (37.6) 22 (42.3)
30 116 (33.4) 42 (38.9) 34 (29.3) 28 (30.1) 12 (23.1)
aMantel-Haenszel chi-square test for trend, otherwise chi-square test for association.
bPercentages obtained from total number of current smokers within each age category.
cPercentages obtained from total number of current drinkers within each age category.
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(r¼ 0.32; P< 0.001) (Fig. 1), with prostate volumes of
50 g or greater occurring exclusively in men ages 55 yr
and older.
Significant age-related decreases in the levels of seve-
ral hormones were observed, including AD (r¼0.19;
P< 0.001), DHEAS (r¼0.35; P< 0.001), FT (r¼0.26;
P< 0.001), E2 (r¼0.11; P¼ 0.044), E1S (r¼0.20; P<
0.001), and PRLN (r¼0.13; P¼ 0.015) (Table III). TT
levels also tended to decrease with age, although this
relationship was of marginal significance (r¼ 0.10;
P¼ 0.062). Levels of SHBG (r¼ 0.17; P< 0.001) and the
ratio of E2 to FT (r¼ 0.13; P¼ 0.018) increased with
age. After age adjustment, prostate volume correlated
positively with AG (r¼ 0.12; P¼ 0.028), E1S (r¼ 0.13;
P¼ 0.018), and the ratio of E2 to TT (r¼ 0.12; P¼ 0.033),
and negatively with SHBG (r¼0.17; P¼ 0.002).
Associations of obesity with altered endogenous sex
hormone levels were also observed. Increasing levels of
BMI were strongly associated with decreases in AD, FT,
TT, and SHBG. Increasing BMI was positively corre-
lated with AG, E2, E1S, and an increasing E2:TT ratio
and E2:FT ratio.
Statistically significant differences in the mean
prostate volume were associated with smoking status,
alcohol drinking status, and BMI (Table IV). Current
and former drinkers had smaller prostates than never
drinkers, although no dose-response relationship was
observed. Higher tertile levels of BMI were also asso-
ciated with larger mean prostate volumes, with average
prostate gland volumes increasing with increasing
BMI tertile, from 24.63 to 28.34 g.
Results from the multivariable linear regression
models indicated that prostatic volume decreased with
increasing levels of SHBG (P¼ 0.011) (Table V). Increas-
ing levels of TT (P¼ 0.058) were marginally associat-
ed with increasing prostate volume. Increasing age
(P< 0.001) was associated with increases in prostate
volume, even after controlling for BMI, IGFBP-3, TT,
and SHBG. Additionally, increasing levels of BMI were
significantly associated with larger prostate volumes
(P¼ 0.021). In multivariable models constructed with
indicator variables to represent the tertile categories of
BMI, a statistically significant difference was not found
when comparing the prostate volumes of overweight
men (BMI between 25 and 29.9 kg/m2) to men with
a BMI of less than 25 kg/m2 (data not presented).
In contrast, obese men (BMI 30 kg/m2) had signifi-
cantly higher prostate volumes compared with men
with a BMI of less than 25 kg/m2. Each unit (kg/m2)
increase in BMI among men with a BMI 30 kg/m2
was a predictor of higher prostate volume (3.74 g). No
TABLE II. SpearmanCorrelationCoeff|cients BetweentheMeasuredHormones*
AG AD DHEAS FT TT E2 E1S E2:TT E2:FT PRLN
AD 0.04 — — — — — — — — —
DHEAS 0.10 0.34a — — — — — — — —
FT 0.01 0.58a 0.33a — — — — — — —
TT 0.01 0.38a 0.05 0.58a — — — — — —
E2 0.07 0.32a 0.21a 0.32a 0.27a — — — — —
E1S 0.04 0.23a 0.59a 0.23a 0.19a 0.38a — — — —
E2:TT 0.06 0.12a 0.05 0.28a 0.67a 0.45a 0.43a — — —
E2:FT 0.08 0.28a 0.18a 0.64a 0.32a 0.44a 0.10 0.65a — —
PRLN 0.02 0.22a 0.08 0.14a 0.09 0.09 0.09 0.04 0.07 —
SHBG 0.02 0.14a 0.15a 0.08 0.60a 0.11a 0.34a 0.45a 0.01 0.10
*AG, androstanediol glucuronide (ng/ml); AD, androstenedione (ng/ml); DHEAS, dehydroepiandrosterone sulfate (mg/dl); FT, free
testosterone (pg/ml); TT, total testosterone (ng/ml); E2, estradiol (pg/ml); E1S, estrone sulfate (pg/ml); E2:TT, estradiol:total
testosterone ratio; E2:FT, estradiol:free testosterone ratio; SHBG, sex hormone-binding globulin (nmol/l); PRLN, prolactin (ng/ml).
aP< 0.05.
Fig. 1. Correlationbetweenmeasuredprostatevolumeandage.
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statistically significant relationship of either tobacco
or alcohol consumption with prostate volume was
observed.
DISCUSSION
In a population-based study, we assessed the nature
of the interrelationships of epidemiologic risk factors
and endogenous sex-steroid hormones with prostate
volume in AA men. Most of the available literature
describing endocrine associations in BPH was based on
Caucasian populations. After adjustment for age and
IGFBP-3, increases in prostate volume were indepen-
dently associated with decreases in the levels of SHBG.
Increases in prostate volume were marginally associat-
ed with increases in the serum levels of TT.
Steroid hormones, in particular androgens and
estrogens, are thought to play major roles in the
development of BPH, but the precise mechanisms by
which each contributes to this process remain unclear.
Testosterone and its potent intraprostatic metabolite
dihydrotestosterone (DHT) stimulate prostatic growth
and are responsible for the maintenance of secondary
sex characteristics. However, as noted by Lagiou and
colleagues [17], the epidemiologic evidence implicat-
ing testosterone in the pathogenesis of BPH was con-
flicting. Potential reasons for discrepancies may be
attributed to observations limited to hospitalized pati-
ents and inappropriate comparison groups, inadequate
control of confounding risk factors, or lack of standar-
dization in diurnal blood sampling and assay metho-
dology [5]. Although our results on the association of
TT with prostate volume failed to reach statistical
significance in bivariate analyses, the marginal signi-
ficance of findings in multivariable analyses suggested
that the cumulative lifetime level of TT, in conjunction
with decreased levels of SHBG, were predictive of risk
of BPH.
It has been demonstrated that DHT is the more
potent androgen metabolite, and after binding to the
TABLE III. SpearmanCorrelations ofHormonesWithAge,BMI, and ProstateVolume*
AG AD DHEAS FT TT E2 E1S E2:TT E2:FT PRLN SHBG
Age (yr) 0.06 0.19a 0.35a 0.26a 0.10 0.11b 0.20a 0.02 0.13b 0.13b 0.17a
BMIc (kg/m2) 0.12b 0.14b 0.03 0.21a 0.39a 0.15d 0.20a 0.47a 0.31a 0.04 0.28a
Prostate volumec (g) 0.12b 0.04 0.08 0.02 0.07 0.09 0.13b 0.12b 0.04 0.08 0.17d





TABLE IV. Mean ProstateVolume (g) and Standard Errors
(SE) for Selected Potential Confounding Factors
Factor
Mean prostate





















aP value in analysis of variance.
TABLE V. Multiple Linear Regression-Derived Beta
Coeff|cients and P Values for Factors Signif|cantly
AssociatedWith ProstateVolume*
Factor Beta coefficienta (SE) P value
Age (yr) 0.01445 (0.00205) <0.001
BMI (kg/m2) 0.00856 (0.00369) 0.021
SHBG (nmol/l) 0.00282 (0.00110) 0.011
TT (ng/ml) 0.00016 (0.00008) 0.058
*Natural log transformation of prostate volume used in regres-
sion analyses. BMI, body mass index; SHBG, sex-hormone
binding globulin; TT, total testosterone.
aModel R-square¼ 0.1752; adjusted for insulin-like growth factor
binding protein-3.
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androgen receptor (AR), the DHT-AR complex stimu-
lates the transcription of a cascade of androgen-
responsive genes. AG is a major metabolite of DHT
and is considered to be a useful marker of DHT activity
[18]. However, circulating levels of AG did not appear
to be significantly related to prostate volume in our
population of AA men but may not accurately reflect
intraprostatic DHT and androstanediol concentration
levels [6,19].
The aging prostate is subjected to the hormo-
nal effects of stromal and epithelial interactions and
of the relatively increasing ratio of estrogens to and-
rogens. Although our initial analyses indicated signi-
ficant correlations of age-adjusted prostate volume
with E1S and the ratio of E2 to TT, multivariable
analyses suggested that prostate volume was not ex-
plained sufficiently by ratios of either E2 to TT or E2
to FT.
In a prior publication, we reported evidence of an
apparent association of serum IGFBP-3 with prostate
enlargement but no association with IGF-1 [11]. Prior
studies investigating peptide growth factors such as
IGF-1 and its major binding protein IGFBP-3 have
underscored the important role of the IGF system
in prostatic neoplasia [20,21]. Prostate cancer risk has
been associated with increased serum IGF-1 levels and
inversely with serum IGFBP-3 levels [22,23]. Two
epidemiologic studies have not demonstrated any rela-
tionship between serum IGF-1 levels and prostate
volume [20] or histologically confirmed BPH [24]. Our
data suggested that increasing levels of IGFBP-3 were
inversely correlated with TT and positively associated
with an elevated E2:TT ratio. Increasing BMI was also
correlated positively with increasing levels of IGFBP-3.
We may hypothesize, therefore, that the apparent asso-
ciation of IGFBP-3 with increased prostatic volume was
indicative of a more direct causal mechanism involving
the interaction of the sex-steroid hormones.
The associations between prostate volume and
endocrine factors observed in this study were not
fully explained by confounding due to age, tobacco
or alcohol consumption, or obesity, although age and
BMI served as independent risk factors for prosta-
tic enlargement. Higher levels of BMI, particularly in
excess of 30 kg/m2 were predictive of increased pros-
tate volumes in the AA men. Approximately 33% of
our study population was classified as being obese
(BMI 30 kg/m2). As noted in two other studies
[25,26], increased BMI was associated with larger pros-
tate volumes. In FMHS AA men, levels of E1S and E2
increased with increasing BMI, whereas serum levels
of both FT and TT declined.
Alcohol consumption and tobacco use are potential
risk factors for BPH and have been postulated to alter
levels of serum sex-steroid hormones. As noted by
several authors [9,12,27], most previous epidemiologic
studies of risk factors for BPH have shown an inverse
association of BPH with use of alcohol and cigarette
smoking. We observed in FMHS participants that
current and former alcohol drinkers had smaller pros-
tates than never drinkers, while current smokers had
smaller prostates than never smokers. However, the
observed associations of cigarette smoking and alcohol
drinking with prostate volume disappeared in multi-
variable analyses.
This study has some limitations. The cross-sectional
nature of this study design did not permit evaluation of
temporal trends based on repeated observations in
subjects. Longitudinal studies of the associations be-
tween endogenous sex steroids, IGF-1, IGFBP-3, and
prostate volume are needed to assess accurately the
impact of these factors on the aging prostate [11].
There was the potential for selection bias, as only half
the eligible subjects completed the clinical phase of the
FMHS protocol. An evaluation of potential selection
bias in the FMHS observed that the participants tend-
ed to be younger and experienced more urologic
symptoms when compared with nonparticipants [13].
Selection bias would have occurred if nonparticipants
differed from participants in the distribution of risk
factors and hormonal profiles in relation to prostate
volumes, which could not be evaluated. Finally, our
most parsimonious multivariable model explained
only 17.5% of the variance in prostate volume, sug-
gesting that unmeasured growth factors or interactive
lifestyle (e.g., dietary) and genetic risk factors play
potentially a facilitating role in the induction and main-
tenance of BPH in AA men.
In summary, the present study observed that serum
levels of SHBG and possibly TT were associated with
increased prostatic volume. Prostatic enlargement in
AA men may involve complex interrelationships of
sex-steroid hormones, increasing age, and BMI. Future
longitudinal studies are needed to fully describe the
temporal relationships of endogenous sex-steroid hor-
mones, IGF-1, IGFBP-3, and potential interactions with
epidemiologic and genetic risk factors in the natural
history of increasing prostatic volume associated with
BPH and lower urinary tract symptom morbidity.
CONCLUSIONS
The natural history of BPH reflects both pathologic
and clinical sequelae of cumulative exposures to a com-
plex of sex-steroid hormones, growth factors, and
binding proteins. The FMHS of AA men underscores
the importance of age and body composition in rela-
tionship to the levels in blood and, presumably, in
prostatic tissue of the hormonal determinants of pros-
tate volume.
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Insulin-like growth factor I is not a useful marker of prostate
cancer in men with elevated levels of prostate-specific antigen.
J Clin Endocrinol Metab 2000; 85:2744–2747.
24. Mantzoros CS, Tzonou A, Signorello LB, Stampfer M,
Trichopoulos D, Adami HO. Insulin-like growth factor-1 in
relation to prostate cancer and benign prostatic hyperplasia. Br J
Cancer 1997;76:1115–1118.
25. Soygur T, Kupeli B, Aydos K, Arikan N, Muftuoglu YZ. Effect of
obesity on prostatic hyperplasia: its relation to sex steroid levels.
Int Urol Nephrol 1996;28:55–59.
26. Daniell HW. Larger prostatic adenomas in obese men with no
associated increase in obstructive uropathy. J Urol 1993;149:315–
317.
27. Meigs JB, Mohr B, Barry MJ, Collins MM, McKinlay JB. Risk
factors for clinical benign prostatic hyperplasia in a community-
based population of healthy aging men. J Clin Epidemiol 2001;
54:935–944.
Sex-SteroidHormones and ProstateVolume 329
